alexa Design And Synthesis Of New 2-substituted Benzimidazoles As Dual Inhibitor For C-Met And VEGFR-2
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

9th Annual European Pharma Congress
June 26-28, 2017 Madrid, Spain

Hanan M Refaat, Heba A Ibrahim, Kamilia Amin and Fadi Awadallah
Future University in Egypt, Egypt
Cairo University, Egypt
Posters & Accepted Abstracts: Pharmaceut Reg Affairs
DOI: 10.4172/2167-7689-C1-025
C-Met (a receptor tyrosine kinase) has been shown to collaborate synergistically with VEGFR-2 (a member of vascular endothelial growth factor receptors belonging also to tyrosine kinase), resulting in promoting development of angiogenesis and progression of various human cancers. In recent years, some c-Met/VEGFR-2 dual inhibitors have been reported or have entered clinical trials. For example Treanda (bendamustine hydrochloride) comprises a benzimidazole ring with a butyric acid substituent and was approved by FDA for the treatment of chronic lymphotic leukemia. The rational design of target molecules was based on its in silico molecular docking study and in silico ADMET study to provide an insight about the binding mode into binding sites of both c-Met/VEGFR-2 as a dual inhibitor. Thus, the benzimidazole ring of bendamustine was retained, buturic acid was replaced by nitro group and the bis-(chloroethyl) amine group (mechlorethamine) was substituted with several biologically active scaffolds such as oxadiazole, thiadiazole, and triazolo-thiadiazines. Five series (5a-b, 7a–o, 10a-d, 13a–b and 15a–c) of 2- substituted benzimidazole derivatives were synthesized via condensation of 4-nitro-o-phenylenediamine with α-ketoglutaric acid. The cytotoxic activities of some of the designed analogues were carried out at the National Cancer Institute (NCI), USA; at a single dose (10 μM), against full NCI 60 human cell lines. Most of the tested compounds, 5b (793196/1), 7i (793197/1), 13a (793191/1), 13f (793193/1), 13i (793192/1), 15a (793199/1) and 15b (793200/1) exhibited significant anti-proliferative activity. Further, all of the prepared compounds are under enzymatic screening for their inhibitory activity for both c-Met and VEGFR-2 as dual inhibitor.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version